Dr. Dongxu Sun is the founder and CEO of Truebinding Inc., where he is leading a team of multi-discipline scientists to develop monoclonal antibody drug candidates targeting novel pathogenic factors for AD and other indications. He has over seventy issued or pending patents covering those antibodies for treatment of neurodegenerative diseases and other indications.
Medical science has made significant strides in the development of advanced treatments over the past decade. However, the majority of FDA-approved treatments for Alzheimer’s focus on the management of symptoms or delayed progression of the disease.